VEA
CNCE

Virtus ETF Advisers’s Concert Pharmaceuticals, Inc. CNCE Stock Holding History

Virtus ETF Advisers’s Portfolio CNCE Stock Details CNCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-20,939
Closed -$212K – 196
2016
Q3 		$212K Hold
20,939
– – 0.1% 137
2016
Q2 		$235K Buy
20,939
+8,275
+65% +$105K 0.17% 110
2016
Q1 		$173K Sell
12,664
-792
-6% -$11.4K 0.24% 107
2015
Q4 		$255K Buy
+13,456
New +$292K 0.7% 62

Other funds holding CNCE

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $2.83B AUM 21.61% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
NI
Numeric Investors Boston, Massachusetts $13.7B AUM 28.88% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
SAM
Senzar Asset Management New York $34.7M AUM 0.56% 1-Year Est. Return

Virtus ETF Advisers's CNCE Position: Q4 2016 in Review

Virtus ETF Advisers sold out of Concert Pharmaceuticals, Inc. (CNCE) in Q4 2016, closing a stake of 20,939 shares — an estimated $212K sold.

Virtus ETF Advisers first reported a position in CNCE in Q4 2015 and held it in 4 quarters. The position peaked at $255K in Q4 2015. 89 funds tracked by Wall St. Rank hold CNCE as of Q4 2016.

  • Virtus ETF Advisers reported no remaining Concert Pharmaceuticals, Inc. position as of Q4 2016 after selling out during the quarter.
  • Virtus ETF Advisers sold 20,939 Concert Pharmaceuticals, Inc. shares in Q4 2016, an estimated $212K.
  • Virtus ETF Advisers first reported a position in Concert Pharmaceuticals, Inc. in Q4 2015 and held it in 4 quarters.
  • Virtus ETF Advisers's Concert Pharmaceuticals, Inc. position peaked at $255K in Q4 2015.
  • 89 funds tracked by Wall St. Rank held Concert Pharmaceuticals, Inc. as of Q4 2016.

Based on Virtus ETF Advisers's 13F filing for Q4 2016, filed 14 Feb 2017.